Las Vegas, NV, October 02, 2015 --(PR.com
)-- Altogen Biosystems has developed a highly efficient in vivo transfection reagent capable of delivery cargo molecules (siRNA, miRNA, pDNA, and small proteins) into multiple tissues including spleen, kidney, pancreas, liver, and tumors. In vivo transfection is a laboratory research method utilized by preclinical research scientists to deliver novel therapeutic molecules into specific tissue. This method is commonly used to perform animal gene silencing (RNAi) studies by transfection of small interfering RNA (siRNA) into cells or tissues.
PEG-Liposome In Vivo Transfection Kit is designed for preclinical research and pharmacology/toxicology testing of new medicines in laboratory mice and rats. It is commercially available from Altogen Biosystems at www.altogen.com/peg-liposome-based-in-vivo-transfection-reagent.php
PEG-Liposome In Vivo Transfection reagent creates complex with negatively charged molecules and encapsulate cargo molecules for efficient tissue-targeted delivery in vivo. This product is optimized for gene silencing studies and RNAi induction by efficient delivery of functional small RNA molecules (siRNA, shRNA, microRNA) into tissues. Liposome component provides in vivo siRNA protection due to efficient siRNA-liposome encapsulation. A remarkable feature of this reagent is reduced innate immune response and low toxicity due to biodegradable PEG modification.
The PEG-Liposome based In Vivo Transfection Kit is manufactured exclusively by Altogen Biosystems (www.altogen.com) and allows for easy, efficient, and pre-optimized in vivo delivery via IV or IP administration. The kit include ready-to-use protocols and this reduces the need for transfection optimizing experiments prior to using the kit.
As a leading provider of preclinical biology research products and services, Altogen Labs (www.altogenlabs.com) ensures quality of all Altogen® in vivo products and services.